Actively Recruiting
Optimizing Fertility-Preserving Treatments for Stage IA Grade 2 Endometrioid Adenocarcinoma A Randomized Trial Comparing Progesterone Monotherapy and Combined Therapy
Led by Peking University People's Hospital · Updated on 2026-08-21
16
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Endometrial cancer is a common gynecological cancer with rising incidence and younger onset age. This research focuses on patients with stage IA grade 2 endometrioid adenocarcinoma who wish to preserve fertility. It aims to find the best fertility-sparing treatment by comparing different therapies, addressing the current uncertainty about treatment for this group. The study randomly assigns participants to one of two treatment groups. One group receives oral medroxyprogesterone acetate or megestrol acetate alone. The other group receives the same oral medication combined with a levonorgestrel intrauterine system placed in the uterus. Each treatment course lasts 3 to 6 months, with evaluations including biopsies, ultrasounds, and MRI scans. Side effects and safety are monitored regularly. Participants undergo regular assessments through endometrial biopsies after each treatment course to check tissue response. Monthly vaginal ultrasounds and occasional pelvic MRI scans help evaluate progress. Researchers measure the time to complete remission as the main outcome, along with remission rates, recurrence, pregnancy outcomes, and changes in blood markers over five years. Safety and treatment adherence are also tracked throughout the study.
CONDITIONS
Brief Title
Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer
Research Team
Y
Yiqin Wang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here